Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Interaction Between Tegoprazan and NSAIDs
NCT04639804Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Jun 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tegoprazan in gastroesophageal reflux disease (GERD) (3 arms), sponsored by HK inno.N Corporation. Primary endpoints: Area Under the Concentration-time Curve Over the Dosing Interval at Day 7 and Maximum Plasma Concentration at Steady State at Day 7. Started Jun 2020; status: completed.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04639804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04639804.